CTBP2 and neoplasm: In colorectal cancer cells, disrupting the CtBP2-G9a interface reduces H3K9me2 deposition at target promoters such as PTEN, leading to transcriptional derepression, attenuation of oncogenic signaling, and impaired tumor cell proliferation.